$APVO

Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 23, 2026, Aptevo Therapeutics Inc. (the “Company”) entered into Amendment No. 6 (the “Amendment”) to the Rights Agreement, dated as of November 8, 2020, between the Company and Broadridge Corporate Issuer Solutions,

Aptevo Therapeutics (Nasdaq:APVO) announced progress in its next-generation trispecific cancer therapy programs, optimizing candidates for scalable manufacturing. The company expects to enter IND-enabling studies for its lead candidate, APVO451, in the first half of 2027. Trispecific therapies combine three cancer-fighting functions in one molecule, offering a coordinated approach to cancer treatment.

Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development Company making critical progress in scalable manufacturing and preparing the lead trispecific candidate for future human testing Trispecifics combine three complementary cancer-fighting

Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On September 22, 2026, Aptevo Therapeutics Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”), at which a quorum was present. Stockholders considered four proposals outlined below, e

Aptevo Therapeutics (APVO) stock fell 17.3% pre-market to $2.15 despite reporting 93% clinical benefit rate in a trial for a treatment-resistant leukemia. The decline is attributed to 'sell the news' reaction, potential dilution from new shares, and bearish technical trends. The broader market showed mild gains, but not enough to offset APVO's challenges.

Aptevo Therapeutics (APVO) reported a 93% clinical benefit rate in TP53-mutated AML patients using its mipletamig triplet, nearly doubling published outcomes for venetoclax and azacitidine. The Phase 1b/2 RAINIER trial is ongoing, with regulatory interaction planned for 1H27. APVO focuses on developing novel immunotherapies for cancer.

Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On August 21, 2026, Aptevo Therapeutics Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. Stockholders considered four proposals outlined below, each o

Aptevo Therapeutics (NASDAQ:APVO) reported 2Q26 financial results and a business update. The company said mipletamig’s RAINIER Phase 1b/2 trial showed 87% clinical benefit and 81% remission in 31 evaluable unfit frontline AML patients, with dose optimization nearing completion and Phase 2 interaction expected in 1Q27. Aptevo appointed a new CSO, received a $1.5M non-dilutive grant for APVO451, and entered a 50/50 Niowave radiopharmaceutical collaboration. Cash was $9.8M at June 30, 2026.

Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results Mipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2 Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology Pipeline Non

Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds SEATTLE, WASHINGTON / ACCESSWIRE / August 12, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) (“Aptevo” or the “Company”), a clinical-stage biotechnology company develo